Verve Therapeutics (VERV) AI Stock Analysis

• Market Cap: $569.63M
• Dividend Yield: N/A
• Average Volume (3M): 2.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.00
• Revenue Growth: 271.44%
• EPS Growth: 26.65%
• Country: US
• Employees: 274
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 89,143,234
• 10 Day Avg. Volume: 3,737,364
• 30 Day Avg. Volume: 2,984,503
• PEG Ratio: -0.35
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.71
• Enterprise Value/Market Cap: 1.78
• Enterprise Value/Revenue: 7.39
• Enterprise Value/Gross Profit: 16.97
• Enterprise Value/Ebitda: -1.18
• 1Y Price Target: $24.00
• Price Target Upside: 275.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 58 Neutral
• Price Target: $6.00 ▼(-6.10%Downside)

Verve Therapeutics' stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company's robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.

Positive Factors

Clinical Trial Success

VERVE-102 data a home run on both safety and efficacy - raising YE25 price target to $39.

Financial Position

With $497.1M on the balance sheet, the Company has the financials to execute on several key upcoming milestones and into mid-2027.

Regulatory Progress

The FDA cleared the IND for VERVE-102, allowing US trial sites to support the Phase 2 initiation slated for H2 2025.

Negative Factors

Development Challenges

Progress with the rest of the pipeline remains on track, with VERVE-201 expected to report interim data from the Ph1b Pulse-1 trial.

Partnership Termination

Vertex has terminated the research collaboration for an in vivo gene-editing program for liver disease due to changing priorities with Verve regaining full rights.

Verve Therapeutics Business Overview & Revenue Model

Company Description

Verve Therapeutics (VERV) is a biotechnology company focused on developing transformative genetic medicines for cardiovascular disease. The company leverages cutting-edge gene editing technologies to create single-course gene-editing medicines that have the potential to permanently reduce the risk of coronary artery disease. Verve's innovative approach aims to address the underlying genetic causes of cardiovascular disease, which is one of the leading causes of mortality worldwide.

How the Company Makes Money

Verve Therapeutics primarily makes money through the development and commercialization of its gene-editing therapies. The company aims to generate revenue by bringing its proprietary therapies to market following successful clinical trials and regulatory approvals. Additionally, Verve may establish partnerships or collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on the commercial success of the therapies. As a biotechnology firm, Verve's revenue model is highly dependent on the advancement of its therapies through clinical development and the ability to secure strategic partnerships.

Verve Therapeutics Financial Statement Overview

Summary

Verve Therapeutics shows strong revenue growth, indicating potential in its sector. However, profitability remains elusive with negative net profit and EBIT margins. The balance sheet is robust with low leverage and high equity, offering financial stability. The company needs to focus on reducing losses to improve overall financial health.

Income Statement

Verve Therapeutics has shown significant revenue growth with a TTM revenue of $59.61M, up from $32.33M in the previous year, marking an 84.39% increase. However, the company remains unprofitable with a negative net profit margin of -303.69% and a negative EBIT margin of -349.67%. The gross profit margin is relatively strong at 100% due to the absence of cost of goods sold, but the company's high operating losses pose a challenge to achieving profitability.

Balance Sheet

The company's balance sheet reflects a healthy equity ratio of 77.11% in the TTM, indicating a strong reliance on equity over debt. The debt-to-equity ratio is low at 0.14, showcasing low leverage risk. However, the return on equity (ROE) is negative at -38.23%, highlighting the ongoing challenges in converting equity into profits.

Cash Flow

Operating cash flow is negative, with a TTM figure of -$142.46M. The free cash flow to net income ratio is 0.81, indicating that the company is able to generate cash relative to its net losses. Additionally, the free cash flow has slightly improved from the previous year, reflecting efforts in managing expenditures despite ongoing cash outflows.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
59.61M	32.33M	11.76M	1.94M	0.00	0.00
	Gross Profit
59.61M	32.33M	6.30M	1.94M	-3.38M	-1.33M
	EBIT
-208.45M	-228.66M	-223.12M	-165.69M	-87.07M	-40.63M
	EBITDA
-201.62M	-221.91M	-217.67M	-162.88M	-85.53M	-39.30M
	Net Income Common Stockholders
-181.01M	-198.71M	-200.07M	-157.39M	-118.64M	-45.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
497.08M	524.28M	623.95M	554.81M	360.44M	72.11M
	Total Assets
614.16M	647.39M	752.69M	679.22M	384.12M	78.41M
	Total Debt
68.64M	69.98M	74.91M	81.92M	1.96M	125.16M
	Net Debt
-27.92M	-102.58M	-131.27M	-33.49M	-62.38M	116.17M
	Total Liabilities
140.65M	153.99M	153.19M	128.29M	26.77M	142.32M
	Stockholders Equity
473.51M	493.40M	599.50M	550.93M	357.35M	-63.91M
Cash Flow		Free Cash Flow
-146.98M	-161.43M	-158.83M	-135.56M	-82.24M	-38.69M
	Operating Cash Flow
-142.46M	-157.69M	-149.55M	-122.33M	-77.88M	-35.27M
	Investing Cash Flow
68.34M	74.88M	27.69M	-155.96M	-239.10M	-51.13M
	Financing Cash Flow
26.47M	49.20M	212.58M	328.96M	377.09M	92.63M

Verve Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERV, the sentiment is Positive. The current price of 6.39 is above the 20-day moving average (MA) of 5.03, above the 50-day MA of 4.72, and above the 200-day MA of 5.70, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 69.24 is Neutral, neither overbought nor oversold. The STOCH value of 88.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERV.

Verve Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	59 Neutral	$682.59M	―	-159.34%	―	-48.97%	69.32%
VERV	58 Neutral	$569.63M	―	-34.26%	―	271.44%	26.65%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
IVA	51 Neutral	$473.84M	―	344.74%	―	-47.32%	-26.67%
RNAC	47 Neutral	$279.53M	―	-938.38%	―	38.82%	-645.78%
OLMA	46 Neutral	$288.05M	―	-41.59%	―	―	0.42%
SANA	33 Underperform	$656.37M	―	-71.44%	―	―	19.94%

Verve Therapeutics Corporate Events

Verve Therapeutics Holds Annual Stockholders Meeting

On June 5, 2025, Verve Therapeutics held its Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Lonnel Coats, Jodie Morrison, and Krishna Yeshwant, M.D. as Class I directors for a three-year term. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified, and the compensation for the company’s named executive officers was approved on an advisory basis.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.